

WEEKLY ANALYSIS REPORT

Vol 10

March 07, 2026

Weekly Investment Ideas

Date	Stock	NSE SYMBOL	Entry Price	Target	Stop Loss
9.3.2026	Bharat Dynamics	BDL	1356	1430	1290
9.3.2026	JSW Infrastructure	JSWINFRA	268	289	250
9.3.2026	Tata Motors Commercial Vehicles	TMCV	474	520	440

NOTE - These Stocks are recommended only for short term investment (Stop Loss should be followed Daily closing basis)

Technical Outlook

Last week, Nifty 50 started on a weak note as it opened with a gap-down near 24659 below its 200-day EMA. Nifty attempted a recovery but could not sustain and remained under pressure. Nifty closed the week at 24450 with a loss of 728 points.

Nifty has closed below all its key averages. It has breached its channel range with the gap-down indicating at weakness. It has also moved below its 55-week EMA, and now remains above 200-week EMA. RSI remains below its average near 35 on daily and 40 on weekly chart, indicating at a weak momentum.

Going forward, 24800-25000 is a strong resistance for Nifty in the near term. Nifty is likely to see support near 24400, below which 24000 will be an important support.



Weekly Market Review

Benchmark declines for second straight week amid West Asia tension and rising crude prices

Domestic equity benchmarks ended with major losses during the week, as heightened geopolitical tensions and a sharp surge in crude oil prices weighed heavily on investor sentiment. From the four trading sessions, the market declined on three days and advanced only once, reflecting a cautious risk-off approach among participants. Escalating conflict in West Asia, particularly involving the United States, Israel and Iran, triggered volatility in global markets and pushed energy prices higher. Persistent foreign institutional investor outflows and a weakening rupee further added to the pressure on equities. Although The market witnessed a brief recovery on Thursday as bargain buying emerged and global sentiment stabilised slightly. However, in the last session of the week, equities again came under heavy selling pressure, tracking higher oil prices and persistent global concerns.

In the week ended on Friday, 06 March 2025, the S&P BSE Sensex dropped 2,368.29 points or 2.91% to settle at 78,918.90. The Nifty 50 index plunged 728.2 points or 2.89% to settle at 24,450.45. The BSE 150 MidCap Index fell 3.11% to close at 15,508.72. The BSE 250 SmallCap index tumbled 3.06% at 6,104.32.

Hero MotoCorp (-3.36%): Recorded a 44% YoY rise in total two-wheeler dispatches, selling 558,216 units compared to 388,068 units in February 2025.

Tata Motors (-6.12%): Total sales reached 63,331 units, up 35% YoY. Notably, EV sales surged 57% to 8,385 units, significantly outpacing the overall passenger vehicle growth.

TVS Motor Company (-2.31%): Registered sales of 529,308 units, marking a 31% increase over the 403,976 units sold in the same month last year.

Bajaj Auto (-1.56%): Reported a 27% increase in total auto sales, moving 4.48 lakh units against 3.52 lakh units in February 2025.

Ashok Leyland (-7.83%): Total sales (domestic and exports) jumped 24% to 22,157 units, compared with 17,903 units sold previously.

Eicher Motors (-4.75%): Its subsidiary, VECV, reported a 23.4% YoY jump in commercial vehicle sales, totalling 9,986 units.

Escorts Kubota (-6.35%): The agri-machinery division saw a 20.4% growth, selling 10,339 units versus 8,590 units in the prior year.

Hyundai Motor India (-3.43%): Total sales hit 66,134 units (+12.6% YoY). While domestic sales rose 9.8%, exports saw a sharp 24.8% increase.

Paras Defence (+17.15%): Incorporated "Paras Semiconductors" to establish an advanced 3D packaging OSAT facility catering to AI, networking, and data centers.

Force Motors (-12.29%): Under pressure after SEBI sought detailed information regarding FY24 financial results, insider lists, and digital databases.

Gujarat Gas (-2.64%): Issued force majeure notices to customers, restricting gas supply starting March 6, 2026, due to the ongoing Middle East conflict.

Angel One (-5.81%): Announced a 20.8% YoY jump in its client base, reaching 36.93 million users in February 2026.

Ramky Infrastructure (+1.68%): Signed an EPC agreement with Maharashtra Industrial Township for works at the Dighi Port Industrial Area.

Natco Pharma (+3.14%) & Aurobindo Pharma (+0.82%): Both companies successfully launched generic Pomalidomide Capsules (Pomalyst) in the U.S. market.

Dr. Reddy's Laboratories (+1.30%): Received an Establishment Inspection Report (EIR) from the USFDA for its Srikakulam formulations facility.

Gland Pharma (-8.37%): Received tentative USFDA approval for its Abbreviated New Drug Application (ANDA) for Brimonidine Tartrate Ophthalmic Solution.

Source: www.capitalmarket.com



Research Analyst: RASHMI CHANDAK rashmi@sajag.co.in | Please carefully read the risk disclosure Document as prescribed by SEBI.



SAJAG SECURITIES PVT. LTD.

33/15 - B, Karve Road, Regent Chambers, Pune - 411004, Tel: 91-20-66014737, Fax: 91-20-25302555

E-mail: business@sajag.co.in, investorgrievance@sajag.co.in

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

Disclaimer (As per SEBI (Research Analyst) Regulations, 2014) Investments in securities markets are subject to market risks and there is no assurance or guarantee that the objectives of the investments/investment products/clients will be achieved. Past performance is not indicative of future returns. Investors are advised to review the Client Agreement and other related documents carefully and, in its entirety, and consult their legal, tax and financial advisers to determine possible legal, tax and financial or any other consequences of investing. This Report has been prepared by Sajag Securities Private Limited, a SEBI-registered Research Analyst (Registration No. **INH000001923**) and is for informational purposes only. The views and opinions expressed herein are those of the author as of the date of publication and are subject to change without notice. This Report does not constitute investment advice or an offer or solicitation for the purchase or sale of any financial instrument or security. The information contained in this Report has been obtained from publicly available sources believed to be reliable, but no representation or warranty, express or implied, is made regarding its accuracy or completeness. Investors should make their own investment decisions based on their specific objectives, financial situation, and needs, and should consult their financial adviser before making any investment decision. Sajag Securities Private Limited accepts no liability whatsoever for any direct or consequential loss or damage arising from any use of any information in this document. While utmost diligence has been exercised regarding the accuracy of information contained in this document, please independently verify such information before relying on it. Analyst Certification: Sajag Securities Pvt Ltd, hereby certifies that all views expressed in this research report reflect personal views about the subject company(ies) or securities, and no part of any compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) expressed herein.

Disclosure of Interest: Unless otherwise specified in Point No. 8 below:

- Neither the Research Analyst(s), Sajag Securities Pvt. Ltd., nor its associates or the relatives of the Research Analyst have any financial interest in the company(ies) covered in this report.
- The Research Analyst, his/her associates, relatives, and Sajag Securities Pvt. Ltd. have no other material conflict of interest at the time of publication of this research report.
- Neither the Research Analyst, Sajag Securities Pvt. Ltd., nor its associates have received any compensation for investment banking, merchant banking, brokerage services, or any other products services from the company(ies) covered in this report in the past twelve months.
- Neither the Research Analyst, Sajag Securities Pvt. Ltd., nor its associates have managed or co-managed any private or public offering of securities for the company(ies) covered in this report in the past twelve months.
- Sajag Securities Pvt. Ltd. or its associates have not received any compensation or other benefits from the company(ies) covered in this report, or from any third party, in connection with this research report.
- The Research Analyst has not served as an Officer, Director, or employee of the company(ies) covered in this research report.
- The Research Analyst and Sajag Securities Pvt. Ltd. have not been engaged in any market-making activity for the company (ies) covered in this research report.
- Details pertaining to Sajag Securities Pvt. Ltd., Research Analyst, and its associates with respect to the companies covered in this research report:

- Compensation received from the company(ies) covered in this research report for investment banking transactions in the past 12 months by Sajag Securities Pvt. Ltd.
- Research Analyst, Sajag Securities Pvt. Ltd., or its associates/relatives collectively hold more than 1% of the company(ies) covered in this research report.
- Compensation received by Sajag Securities Pvt. Ltd. or its associates from the company(ies) covered in this research report.
- Sajag Securities Pvt. Ltd. or its affiliates managed or co-managed, in the previous twelve months, a private or public offering of securities for the company(ies) covered in this research report.
- Research Analyst, his/her associates, Sajag Securities Pvt. Ltd., or its associates received compensation for investment banking, merchant banking, brokerage services, or any other products/services from the company(ies) covered in this research report in the past twelve months.